<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHYSICIAN EZ USE JOINT TUNNEL AND TRIGGER KIT- <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, lidocaine hydrochloride, triamcinolone acetonide, povidone-iodineÂ 
			Â </strong><br>MedChem Manufacturing Inc. dba Enovachem<br></p></div>
<h1>KENALOG<span class="Sup">Â®</span>-40 INJECTION <br>(triamcinolone acetonide injectable suspension, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d1"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">NOT FOR USE IN NEONATES</span><br><span class="Bold">CONTAINS BENZYL ALCOHOL</span></p>
<p><span class="Bold">For Intramuscular or Intra-articular Use Only</span><br><span class="Bold">NOT FOR INTRAVENOUS, INTRADERMAL, INTRAOCULAR, EPIDURAL, OR INTRATHECAL USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Kenalog<span class="Sup">Â®</span>-40 Injection (triamcinolone
acetonide injectable suspension, USP) is a synthetic glucocorticoid corticosteroid
with anti-inflammatory action. THIS FORMULATION IS SUITABLE FOR INTRAMUSCULAR
AND INTRA-ARTICULAR USE ONLY. THIS FORMULATION IS NOT FOR INTRADERMAL INJECTION.</p>
<p>Each mL of the sterile aqueous suspension provides 40 mg triamcinolone
acetonide, with 0.65% sodium chloride for isotonicity, 0.99% (w/v) benzyl alcohol
as a preservative, 0.75% carboxymethylcellulose sodium, and 0.04% polysorbate
80. Sodium hydroxide or hydrochloric acid may be present to adjust pH to 5.0 to 7.5.
At the time of manufacture, the air in the container is replaced by nitrogen.</p>
<p>The chemical name for triamcinolone acetonide is 9-Fluoro-11Î²,16Î±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
cyclic 16,17-acetal with acetone. Its structural formula is:</p>
<div class="Figure">
<img alt="triamcinolone acetonide chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-01.jpg"><p class="MultiMediaCaption">MW 434.50</p>
</div>
<p>Triamcinolone acetonide occurs as a white to cream-colored, crystalline
powder having not more than a slight odor and is practically insoluble in
water and very soluble in alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Glucocorticoids, naturally occurring and synthetic, are adrenocortical
steroids that are readily absorbed from the gastrointestinal tract.</p>
<p>Naturally occurring glucocorticoids (hydrocortisone and cortisone),
which also have salt-retaining properties, are used as replacement
therapy in adrenocortical deficiency states. Synthetic analogs such as triamcinolone
are primarily used for their anti-inflammatory effects in disorders of many
organ systems.</p>
<p>Kenalog-40 Injection has an extended duration of effect which may be sustained over a period
of several weeks. Studies indicate that following a single intramuscular dose
of 60 mg to 100 mg of triamcinolone acetonide, adrenal suppression occurs within
24 to 48 hours and then gradually returns to normal, usually in 30 to 40 days.
This finding correlates closely with the extended duration of therapeutic
action achieved with the drug.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3.1"></a><a name="section-4.1"></a><p></p>
<h2>Intramuscular</h2>
<p class="First">Where oral therapy is not feasible, injectable corticosteroid therapy,
including Kenalog-40 Injection (triamcinolone acetonide injectable suspension,
USP) is indicated<span class="Bold"> for intramuscular use</span> as follows:</p>
<p><span class="Italics">Allergic states:</span> Control of severe or incapacitating
allergic conditions intractable to adequate trials of conventional treatment
in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions,
perennial or <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span>.</p>
<p><span class="Italics">Dermatologic diseases: </span><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis,
exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>
(<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span>:</span> Primary or secondary adrenocortical
insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic
analogs may be used in conjunction with mineralocorticoids where applicable;
in infancy, mineralocorticoid supplementation is of particular importance),
congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer, nonsuppurative
<span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
<p><span class="Italics">Gastrointestinal diseases:</span> To tide the patient
over a critical period of the disease in <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> and ulcerative
<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p><span class="Italics">Hematologic disorders:</span> Acquired (autoimmune) hemolytic
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, selected cases of
secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Miscellaneous:</span> Trichinosis with neurologic or
myocardial involvement, tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or
impending block when used with appropriate antituberculous chemotherapy.</p>
<p><span class="Italics">Neoplastic diseases:</span> For the palliative management
of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
<p><span class="Italics">Nervous system: </span>Acute exacerbations of multiple
sclerosis; <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> or craniotomy.</p>
<p><span class="Italics">Ophthalmic diseases:</span> Sympathetic ophthalmia, temporal
<span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and ocular inflammatory conditions unresponsive to topical
corticosteroids.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal diseases</span>:</span> To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission
of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
<p><span class="Italics">Respiratory diseases:</span> Berylliosis, fulminating
or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate
antituberculous chemotherapy, idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>, symptomatic
<span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
<p><span class="Italics">Rheumatic disorders:</span> As adjunctive therapy for
short-term administration (to tide the patient over an acute episode or exacerbation)
in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>; acute rheumatic carditis; <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>;
<span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>
(selected cases may require low-dose maintenance therapy). For the treatment
of <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3.2"></a><a name="section-4.2"></a><p></p>
<h2>Intra-Articular</h2>
<p class="First"><span class="Bold">The intra-articular or soft tissue administration</span> of
Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide
the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>,
acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">epicondylitis</span>,
<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span>, or <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Kenalog-40 Injection is contraindicated in patients who are hypersensitive to any components
of this product (see <span class="Bold"><a href="#s5.1">WARNINGS: General</a></span>).</p>
<p>Intramuscular corticosteroid preparations are contraindicated for
<span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Exposure to excessive amounts of benzyl alcohol has been associated
with toxicity (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>), particularly in neonates,
and an increased incidence of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>, particularly in small preterm infants.
There have been rare reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, primarily in preterm infants, associated
with exposure to excessive amounts of benzyl alcohol. The amount of benzyl
alcohol from medications is usually considered negligible compared to that
received in flush solutions containing benzyl alcohol. Administration of high
dosages of medications containing this preservative must take into account
the total amount of benzyl alcohol administered. The amount of benzyl alcohol
at which toxicity may occur is not known. If the patient requires more than
the recommended dosages or other medications containing this preservative,
the practitioner must consider the daily metabolic load of benzyl alcohol
from these combined sources (see <span class="Bold"><a href="#s6.6">PRECAUTIONS: Pediatric Use</a></span>).</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred in patients receiving corticosteroid therapy (see <span class="Bold"><a href="#s7">ADVERSE REACTIONS</a></span>). Cases of serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration.</p>
<p>Because Kenalog-40 Injection (triamcinolone acetonide injectable
suspension, USP) is a suspension, it should <span class="Bold">not</span> be administered
intravenously.</p>
<p>Unless a <span class="Bold">deep</span> intramuscular injection is given, local
<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> is likely to occur. (For recommendations on injection techniques,
see <span class="Bold"><a href="#s9">DOSAGE AND ADMINISTRATION</a></span>.) Due to
the significantly higher incidence of local <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> when the material is injected
into the deltoid area, this injection site should be avoided in favor of the
gluteal area.</p>
<p>Increased dosage of rapidly acting corticosteroids is indicated
in patients on corticosteroid therapy subjected to any unusual stress before,
during, and after the stressful situation. Kenalog-40 Injection is a long-acting preparation, and is
not suitable for use in acute stress situations. To avoid drug-induced adrenal
insufficiency, supportive dosage may be required in times of stress (such
as <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or severe illness) both during treatment with Kenalog-40
Injection and for a year afterwards.</p>
<p>Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an intravenous corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> who were determined not to have other clear indications for corticosteroid treatment. High doses of systemic corticosteroids, including Kenalog-40 Injection, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-6.2"></a><p></p>
<h2>Cardio-Renal</h2>
<p class="First">Average and large doses of corticosteroids can cause elevation
of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium.
These effects are less likely to occur with the synthetic derivatives except
when they are used in large doses. Dietary salt restriction and potassium
supplementation may be necessary (see <span class="Bold"><a href="#s6">PRECAUTIONS</a></span>).
All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use
of corticosteroids and left ventricular free wall rupture after a recent myocardial
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>; therefore, therapy with corticosteroids should be used with great
caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-6.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Corticosteroids can produce reversible hypothalamic-pituitary-adrenal
(HPA) axis suppression with the potential for glucocorticosteroid insufficiency
after withdrawal of treatment.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid
patients and increased in hyperthyroid patients. Changes in thyroid status
of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.1"></a><a name="section-6.4.1"></a><p></p>
<h3>General</h3>
<p class="First">Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>
than are healthy individuals. There may be decreased resistance and inability
to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen
(viral, bacterial, fungal, protozoan, or helminthic) in any location of the
body may be associated with the use of corticosteroids alone or in combination
with other immunosuppressive agents. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe.
With increasing doses of corticosteroids, the rate of occurrence of infectious
complications increases. Corticosteroids may also mask some signs of current
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.2"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h3>
<p class="First">Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore
should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed
to control drug reactions. There have been cases reported in which concomitant
use of amphotericin B and hydrocortisone was followed by cardiac enlargement
and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see <span class="Bold"><a href="#s6.2">PRECAUTIONS: Drug Interactions:</a></span><span class="Italics"><a href="#s6.2"> Amphotericin B injection and potassium-depleting agents</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.3"></a><a name="section-6.4.3"></a><p></p>
<h3> Special Pathogens</h3>
<p class="First">Latent disease may be activated or there may be an exacerbation
of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by <span class="Italics">Amoeba</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>, <span class="Italics">Cryptococcus</span>, <span class="Italics">Mycobacterium</span>, <span class="Italics">Nocardia</span>, <span class="Italics">Pneumocystis</span>, or <span class="Italics">Toxoplasma</span>.</p>
<p>It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be
ruled out before initiating corticosteroid therapy in any patient who has
spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients
with known or suspected <span class="Italics">Strongyloides</span> (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>.
In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to<span class="Italics"> Strongyloides</span> hyperinfection
and dissemination with widespread larval migration, often accompanied by severe
<span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.4"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h3>
<p class="First">The use of corticosteroids in patients with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>
should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span>
in which the corticosteroid is used for the management of the disease in conjunction
with an appropriate anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> regimen. If corticosteroids are indicated
in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation
is necessary as reactivation of the disease may occur. During prolonged corticosteroid
therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.5"></a><a name="section-6.4.5"></a><p></p>
<h3>Vaccination</h3>
<p class="First"><span class="Bold">Administration of live or live, attenuated vaccines is contraindicated
in patients receiving immunosuppressive doses of corticosteroids. Killed or
inactivated vaccines may be administered. However, the response to such vaccines
cannot be predicted.</span> Immunization procedures may be undertaken in patients
who are receiving corticosteroids as replacement therapy, eg, for Addisonâ€™s
disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6.6"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></h3>
<p class="First">Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course
in pediatric and adult patients on corticosteroids. In pediatric and adult
patients who have not had these diseases, particular care should be taken
to avoid exposure. The contribution of the underlying disease and/or prior
corticosteroid treatment to the risk is also not known. If exposed to chicken
pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated.
If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated.
(See the respective package inserts for complete VZIG and IG prescribing information.)
If chicken pox develops, treatment with antiviral agents should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-6.5"></a><p></p>
<h2>Neurologic</h2>
<p class="First">Epidural and intrathecal administration of this product is not recommended. Reports of serious medical events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been associated with epidural and intrathecal routes of corticosteroid administration (see <span class="Bold"><a href="#s7">ADVERSE REACTIONS:</a></span><span class="Italics"><a href="#s7"> Gastrointestinal </a></span>and <span class="Italics"><a href="#s7">Neurologic/Psychiatric</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.8"></a><a name="section-6.6"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>,
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment
of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. The use
of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>
and may lead to an increase in the risk of new episodes. Corticosteroids should
not be used in active ocular herpes simplex.</p>
<p>Adequate studies to demonstrate the safety of Kenalog Injection
use by intraturbinal, subconjunctival, sub-Tenons, retrobulbar, and intraocular
(intravitreal) injections have not been performed. <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span>, <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>,
<span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>
have been reported with intravitreal administration. Administration
of Kenalog Injection intraocularly or into the nasal turbinates is not recommended.</p>
<p>Intraocular injection of corticosteroid formulations containing benzyl alcohol, such as Kenalog Injection, is not recommended because of potential toxicity from the benzyl alcohol.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s6.0"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">This product, like many other steroid formulations, is sensitive
to heat. Therefore, it should not be autoclaved when it is desirable to sterilize
the exterior of the vial.</p>
<p>The lowest possible dose of corticosteroid should be used to control
the condition under treatment. When reduction in dosage is possible, the reduction
should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent
on the size of the dose and the duration of treatment, a risk/benefit decision
must be made in each individual case as to dose and duration of treatment
and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposiâ€™s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients
receiving corticosteroid therapy, most often for chronic conditions. Discontinuation
of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.01"></a><a name="section-7.2"></a><p></p>
<h2>Cardio-Renal</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may
occur in patients receiving corticosteroids, these agents should be used with
caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or renal
insufficiency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.02"></a><a name="section-7.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized
by gradual reduction of dosage. This type of relative insufficiency may persist
for months after discontinuation of therapy; therefore, in any situation of
stress occurring during that period, hormone therapy should be reinstituted.
Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid
should be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.03"></a><a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Steroids should be used with caution in active or latent peptic
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific ulcerative
<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, since they may increase the risk of a perforation.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>
in patients receiving corticosteroids may be minimal or absent.</p>
<p>There is an enhanced effect of corticosteroids in patients with
cirrhosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.04"></a><a name="section-7.5"></a><p></p>
<h2>Intra-Articular and Soft Tissue Administration</h2>
<p class="First">Intra-articularly injected corticosteroids may be systemically
absorbed.</p>
<p>Appropriate examination of any joint fluid present is necessary
to exclude a septic process.</p>
<p>A marked increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> accompanied by <span class="product-label-link" type="condition" conceptid="4200520" conceptname="Neck swelling">local swelling</span>, further
restriction of joint motion, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are suggestive of <span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">septic arthritis</span>.
If this complication occurs and the diagnosis of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> is confirmed, appropriate
antimicrobial therapy should be instituted.</p>
<p>Injection of a steroid into an infected site is to be avoided.
Local injection of a steroid into a previously infected joint is not usually
recommended.</p>
<p>Corticosteroid injection into unstable joints is generally not
recommended.</p>
<p>Intra-articular injection may result in damage to joint tissues
(see <span class="Bold"><a href="#s7">ADVERSE REACTIONS:</a></span><span class="Italics"><a href="#s7"> Musculoskeletal</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.05"></a><a name="section-7.6"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption
both through their effect on calcium regulation (ie, decreasing absorption
and increasing excretion) and inhibition of osteoblast function. This, together
with a decrease in the protein matrix of the bone secondary to an increase
in protein catabolism, and reduced sex hormone production, may lead to inhibition
of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at
any age. Special consideration should be given to patients at increased risk
of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (ie, postmenopausal women) before initiating corticosteroid
therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.06"></a><a name="section-7.7"></a><p></p>
<h2>Neuro-Psychiatric</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids
to be effective in speeding the resolution of acute exacerbations of multiple
sclerosis, they do not show that they affect the ultimate outcome or natural
history of the disease. The studies do show that relatively high doses of
corticosteroids are necessary to demonstrate a significant effect. (See <span class="Bold"><a href="#s9">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses
of corticosteroids, most often occurring in patients with disorders of neuromuscular
transmission (eg, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant
therapy with neuromuscular blocking drugs (eg, pancuronium). This acute
<span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is generalized, may involve ocular and respiratory muscles, and may
result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical
improvement or recovery after stopping corticosteroids may require weeks to
years.</p>
<p>Psychiatric derangements may appear when corticosteroids are used,
ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>
or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.07"></a><a name="section-7.8"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Intraocular pressure may become elevated in some individuals. If
steroid therapy is continued for more than 6 weeks, intraocular pressure should
be monitored.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s6.1"></a><a name="section-7.9"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be warned not to discontinue the use of corticosteroids
abruptly or without medical supervision, to advise any medical attendants
that they are taking corticosteroids, and to seek medical advice at once should
they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Persons who are on corticosteroids should be warned to avoid exposure
to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are
exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s6.2"></a><a name="section-7.10"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">Aminoglutethimide:</span> Aminoglutethimide may lead
to a loss of corticosteroid-induced adrenal suppression.</p>
<p><span class="Italics">Amphotericin B injection and potassium-depleting agents:</span> When
corticosteroids are administered concomitantly with potassium-depleting agents
(ie, amphotericin B, diuretics), patients should be observed closely for
development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. There have been cases reported in which concomitant
use of amphotericin B and hydrocortisone was followed by cardiac enlargement
and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p><span class="Italics">Antibiotics:</span> Macrolide antibiotics have been reported
to cause a significant decrease in corticosteroid clearance.</p>
<p><span class="Italics">Anticholinesterases:</span> Concomitant use of anticholinesterase
agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>
gravis. If possible, anticholinesterase agents should be withdrawn at least
24 hours before initiating corticosteroid therapy.</p>
<p><span class="Italics">Anticoagulants, oral:</span> Coadministration of corticosteroids
and warfarin usually results in inhibition of response to warfarin, although
there have been some conflicting reports. Therefore, coagulation indices should
be monitored frequently to maintain the desired anticoagulant effect.</p>
<p><span class="Italics">Antidiabetics:</span> Because corticosteroids may increase
blood glucose concentrations, dosage adjustments of antidiabetic agents may
be required.</p>
<p><span class="Italics">Antitubercular drugs:</span> Serum concentrations of
isoniazid may be decreased.</p>
<p><span class="Italics">Cholestyramine:</span> Cholestyramine may increase the
clearance of corticosteroids.</p>
<p><span class="Italics">Cyclosporine:</span> <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine
and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>
have been reported with this concurrent use.</p>
<p><span class="Italics">Digitalis glycosides:</span> Patients on digitalis glycosides
may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Estrogens, including oral contraceptives:</span> Estrogens
may decrease the hepatic metabolism of certain corticosteroids, thereby increasing
their effect.</p>
<p><span class="Italics">Hepatic enzyme inducers (eg, barbiturates, phenytoin,
carbamazepine, rifampin):</span> Drugs which induce hepatic microsomal drug
metabolizing enzyme activity may enhance the metabolism of corticosteroids
and require that the dosage of the corticosteroid be increased.</p>
<p><span class="Italics">Ketoconazole:</span> Ketoconazole has been reported to
decrease the metabolism of certain corticosteroids by up to 60%, leading to
an increased risk of corticosteroid side effects.</p>
<p><span class="Italics">Nonsteroidal anti-inflammatory drugs (NSAIDs): </span>Concomitant
use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids
increases the risk of gastrointestinal side effects. Aspirin should be used
cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The
clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
<p><span class="Italics">Skin tests:</span> Corticosteroids may suppress reactions
to skin tests.</p>
<p><span class="Italics">Vaccines:</span> Patients on prolonged corticosteroid
therapy may exhibit a diminished response to toxoids and live or inactivated
vaccines due to inhibition of antibody response. Corticosteroids may also
potentiate the replication of some organisms contained in live attenuated
vaccines. Routine administration of vaccines or toxoids should be deferred
until corticosteroid therapy is discontinued if possible (see <span class="Bold"><a href="#s5.6.5">WARNINGS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Vaccination</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s6.3"></a><a name="section-7.11"></a><p></p>
<h2> Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine
whether corticosteroids have a potential for carcinogenesis or mutagenesis.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa
in some patients.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s6.4"></a><a name="section-7.12"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s6.4.1"></a><a name="section-7.12.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category C</h3>
<p class="First">Corticosteroids have been shown to be teratogenic in many species
when given in doses equivalent to the human dose. Animal studies in which
corticosteroids have been given to pregnant mice, rats, and rabbits have yielded
an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring. There are no adequate
and well-controlled studies in pregnant women. Corticosteroids should be used
during pregnancy only if the potential benefit justifies the potential risk
to the fetus. Infants born to mothers who have received corticosteroids during
pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s6.5"></a><a name="section-7.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk
and could suppress growth, interfere with endogenous corticosteroid production,
or cause other untoward effects. Caution should be exercised when corticosteroids
are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s6.6"></a><a name="section-7.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">This product contains benzyl alcohol as a preservative. Benzyl
alcohol, a component of this product, has been associated with serious adverse
events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly in pediatric patients. The â€œgasping
syndromeâ€? (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, metabolic
<span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its
metabolites found in the blood and urine) has been associated with benzyl
alcohol dosages &gt;99 mg/kg/day in neonates and low-birth-weight neonates. Additional
symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, intracranial
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>,
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. Although normal therapeutic
doses of this product deliver amounts of benzyl alcohol that are substantially
lower than those reported in association with the â€œgasping syndrome,â€?
the minimum amount of benzyl alcohol at which toxicity may occur is not known.
Premature and low-birth-weight infants, as well as patients receiving high
dosages, may be more likely to develop toxicity. Practitioners administering
this and other medications containing benzyl alcohol should consider the combined
daily metabolic load of benzyl alcohol from all sources.</p>
<p>The efficacy and safety of corticosteroids in the pediatric population
are based on the well-established course of effect of corticosteroids which
is similar in pediatric and adult populations. Published studies provide evidence
of efficacy and safety in pediatric patients for the treatment of nephrotic
syndrome (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month
of age). Other indications for pediatric use of corticosteroids, eg, severe
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted
in adults, on the premises that the course of the diseases and their pathophysiology
are considered to be substantially similar in both populations.</p>
<p>The adverse effects of corticosteroids in pediatric patients are
similar to those in adults (see<span class="Bold"><a href="#s7"> ADVERSE REACTIONS</a></span>).
Like adults, pediatric patients should be carefully observed with frequent
measurements of blood pressure, weight, height, intraocular pressure, and
clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances,
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Pediatric patients
who are treated with corticosteroids by any route, including systemically
administered corticosteroids, may experience a decrease in their growth velocity.
This negative impact of corticosteroids on growth has been observed at low
systemic doses and in the absence of laboratory evidence of HPA axis suppression
(ie, cosyntropin stimulation and basal cortisol plasma levels). Growth velocity
may therefore be a more sensitive indicator of systemic corticosteroid exposure
in pediatric patients than some commonly used tests of HPA axis function.
The linear growth of pediatric patients treated with corticosteroids should
be monitored, and the potential growth effects of prolonged treatment should
be weighed against clinical benefits obtained and the availability of treatment
alternatives. In order to minimize the potential growth effects of corticosteroids,
pediatric patients should be <span class="Italics">titrated</span> to the lowest effective
dose.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s6.7"></a><a name="section-7.15"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness were observed
between elderly subjects and younger subjects, and other reported clinical
experience has not identified differences in responses between the elderly
and younger patients, but greater sensitivity of some older individuals cannot
be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s7"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">(listed alphabetically under each subsection)</span></p>
<p>The following adverse reactions may be associated with corticosteroid
therapy:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, cardiac
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>,
<span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants,
<span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see <span class="Bold"><a href="#s5">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>,
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous
and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>,
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased
<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>-like lesions, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>,
<span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp
hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Endocrine:</span> Decreased carbohydrate and glucose
tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>,
increased requirements for insulin or oral hypoglycemic agents in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>,
manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus, menstrual irregularities, secondary
adrenocortical and pituitary unresponsiveness (particularly in times of stress,
as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients.</p>
<p><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>:</span> Congestive
<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>,
potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, bowel/bladder
dysfunction (after intrathecal administration [see <span class="Bold"><a href="#s5.7">WARNINGS: Neurologic</a></span>]), elevation in serum liver enzyme
levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, increased
appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in
patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Italics">Metabolic:</span> Negative nitrogen balance due to protein
catabolism.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and
humeral heads, <span class="product-label-link" type="condition" conceptid="4280820" conceptname="Calcinosis">calcinosis</span> (following intra-articular or intralesional use),
Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>,
pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, post injection flare (following intra-articular
use), <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
<p><span class="Italics">Neurologic/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>,
<span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>
with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of
treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, personality
changes, psychiatric disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>,
and <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> have occurred after intrathecal administration. <span class="product-label-link" type="condition" conceptid="4269209" conceptname="Acute infarction of spinal cord">Spinal cord infarction</span>, <span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, <span class="product-label-link" type="condition" conceptid="374914" conceptname="Tetraplegia">quadriplegia</span>, <span class="product-label-link" type="condition" conceptid="253482" conceptname="Cortical blindness">cortical blindness</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (including brainstem) have been reported after epidural administration of corticosteroids (see <span class="Bold"><a href="#s5.7">WARNINGS: Neurologic</a></span>).</p>
<p><span class="Italics">Ophthalmic:</span> <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, increased
intraocular pressure, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>
associated with periocular injections.</p>
<p><span class="Italics">Other:</span> Abnormal fat deposits, decreased resistance
to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa,
<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s8"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Treatment of acute overdosage is by supportive and symptomatic
therapy. For chronic overdosage in the face of severe disease requiring continuous
steroid therapy, the dosage of the corticosteroid may be reduced only temporarily,
or alternate day treatment may be introduced.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s9"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.1"></a><a name="section-10.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold">NOTE: CONTAINS BENZYL ALCOHOL (see <a href="#s6">PRECAUTIONS</a>).</span></p>
<p>The initial dose of Kenalog-40 Injection may vary from 2.5 mg to 100 mg per day depending
on the specific disease entity being treated (see <span class="Bold"><a href="#s9.2">Dosage</a></span> section
below). However, in certain overwhelming, acute, life-threatening situations,
administration in dosages exceeding the usual dosages may be justified and
may be in multiples of the oral dosages.</p>
<p><span class="Bold">IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE
AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND
THE RESPONSE OF THE PATIENT.</span> After a favorable response is noted, the
proper maintenance dosage should be determined by decreasing the initial drug
dosage in small decrements at appropriate time intervals until the lowest
dosage which will maintain an adequate clinical response is reached. Situations
which may make dosage adjustments necessary are changes in clinical status
secondary to remissions or exacerbations in the disease process, the patientâ€™s
individual drug responsiveness, and the effect of patient exposure to stressful
situations not directly related to the disease entity under treatment. In
this latter situation it may be necessary to increase the dosage of the corticosteroid
for a period of time consistent with the patientâ€™s condition. If after long-term
therapy the drug is to be stopped, it is recommended that it be withdrawn
gradually rather than abruptly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.2"></a><a name="section-10.2"></a><p></p>
<h2>Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.2.1"></a><a name="section-10.2.1"></a><p></p>
<h3>SYSTEMIC</h3>
<p class="First">The suggested initial dose is 60 mg, <span class="Bold">injected deeply into
the gluteal muscle</span>. <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> of subcutaneous fat may occur if the injection
is not properly given. Dosage is usually adjusted within the range of 40 mg to
80 mg, depending upon patient response and duration of relief. However, some
patients may be well controlled on doses as low as 20 mg or less.</p>
<p><span class="product-label-link" type="condition" conceptid="256439" conceptname="Allergic rhinitis due to pollen">Hay fever</span> or pollen <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>: Patients with <span class="product-label-link" type="condition" conceptid="256439" conceptname="Allergic rhinitis due to pollen">hay fever</span> or pollen <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
who are not responding to pollen administration and other conventional therapy
may obtain a remission of symptoms lasting throughout the pollen season after
a single injection of 40 mg to 100 mg.</p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>,
daily doses of 160 mg of triamcinolone for a week followed by 64 mg every
other day for one month are recommended (see <span class="Bold"><a href="#s6.06">PRECAUTIONS:
Neuro-Psychiatric</a></span>).</p>
<p>In pediatric patients, the initial dose of triamcinolone may vary
depending on the specific disease entity being treated. The range of initial
doses is 0.11 to 1.6 mg/kg/day in 3 or 4 divided doses (3.2 to 48 mg/m<span class="Sup">2</span>bsa/day).</p>
<p><span class="Italics">For the purpose of comparison, the following is the equivalent
milligram dosage of the various glucocorticoids:</span></p>
<table border="0" cellpadding="2" cellspacing="1" width="65%">
<colgroup>
<col width="50%">
<col width="50%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Cortisone, 25</span></td>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Triamcinolone, 4</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Hydrocortisone, 20</span></td>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Paramethasone, 2</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Prednisolone, 5</span></td>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Betamethasone, 0.75</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"><span class="Italics">Prednisone, 5</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Italics">Dexamethasone,
0.75</span></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Italics">Methylprednisolone,
4</span></td></tr>
</tbody>
</table>
<p><span class="Italics">These dose relationships apply only to oral or intravenous
administration of these compounds. When these substances or their derivatives
are injected intramuscularly or into joint spaces, their relative properties
may be greatly altered.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.2.2"></a><a name="section-10.2.2"></a><p></p>
<h3>LOCAL</h3>
<p class="First"><span class="Bold">Intra-articular administration:</span> A single local injection
of triamcinolone acetonide is frequently sufficient, but several injections
may be needed for adequate relief of symptoms.</p>
<p><span class="Bold">Initial dose:</span> 2.5 mg to 5 mg for smaller joints and from
5 mg to 15 mg for larger joints, depending on the specific disease entity being
treated. For adults, doses up to 10 mg for smaller areas and up to 40 mg for
larger areas have usually been sufficient. Single injections into several
joints, up to a total of 80 mg, have been given.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.3"></a><a name="section-10.3"></a><p></p>
<h2>Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.3.1"></a><a name="section-10.3.1"></a><p></p>
<h3>GENERAL</h3>
<p class="First"><span class="Bold">STRICT ASEPTIC TECHNIQUE IS MANDATORY.</span> The vial should
be shaken before use to ensure a uniform suspension. Prior to withdrawal,
the suspension should be inspected for clumping or granular appearance (agglomeration).
An agglomerated product results from exposure to freezing temperatures and
should not be used. After withdrawal, Kenalog-40 Injection should be injected without delay to
prevent settling in the syringe. Careful technique should be employed to avoid
the possibility of entering a blood vessel or introducing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.3.2"></a><a name="section-10.3.2"></a><p></p>
<h3> SYSTEMIC</h3>
<p class="First">For systemic therapy, injection should be made <span class="Bold">deeply into
the gluteal muscle</span> (see <span class="Bold"><a href="#s5">WARNINGS</a></span>).
For adults, a minimum needle length of 1Â½ inches is recommended. In obese
patients, a longer needle may be required. Use alternative sites for subsequent
injections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9.3.3"></a><a name="section-10.3.3"></a><p></p>
<h3>LOCAL</h3>
<p class="First">For treatment of joints, the usual intra-articular injection technique
should be followed. If an excessive amount of synovial fluid is present in
the joint, some, but not all, should be aspirated to aid in the relief of
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and to prevent undue dilution of the steroid.</p>
<p>With intra-articular administration, prior use of a local anesthetic
may often be desirable. Care should be taken with this kind of injection,
particularly in the deltoid region, to avoid injecting the suspension into
the tissues surrounding the site, since this may lead to tissue <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
<p>In treating acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, care should be taken
to ensure that the injection of the corticosteroid is made into the tendon
sheath rather than the tendon substance. <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span> may be treated by infiltrating
the preparation into the area of greatest <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s10"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Kenalog<span class="Sup">Â®</span>-40 Injection (triamcinolone
acetonide injectable suspension, USP) is supplied in vials providing 40 mg
triamcinolone acetonide per mL.</p>
<table border="0" cellpadding="2" cellspacing="1" width="70%">
<colgroup>
<col width="30%">
<col width="49%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td align="left" colspan="1" rowspan="1">Â Â Â Â Â Â Â Â Â Â 40
mg/mL, 1 mL vial</td>
<td align="left" colspan="1" rowspan="1">NDC 0003-0293-05</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Â Â Â Â Â Â Â 40
mg/mL, 5 mL vial</td>
<td align="left" colspan="1" rowspan="1">NDC 0003-0293-20</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">Â Â Â Â Â Â Â Â Â Â 40
mg/mL, 10 mL vial</td>
<td align="left" colspan="1" rowspan="1">NDC 0003-0293-28</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s10.1"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at controlled room temperature, 20Â°â€“25Â°C
(68Â°â€“77Â°F), avoid freezing and protect from light. Do not refrigerate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA<br>Product of Italy</p>
<p>1221153A5</p>
<p>Rev August 2011</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e8ec904c-dc9b-423b-a953-d9f32bf6b4a8"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">AQUEOUS SOLUTIONS FOR INFILTRATION</span></span></p>
<p><span class="Bold"><span class="Emphasis">AND NERVE BLOCK</span></span></p>
<p><span class="Bold"><span class="Emphasis">Ampul</span></span></p>
<p><span class="Bold"><span class="Emphasis">Plastic Multiple-dose Fliptop Vial</span></span></p>
<p><span class="Bold"><span class="Emphasis">Glass Teartop Vial</span></span></p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="fa3a270a-1a49-4094-992a-6cdfb17b6896"></a><a name="section-14"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of lidocaine hydrochloride in water for injection for parenteral administration in various concentrations with characteristics as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">0.5%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">1%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">1.5%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">2%</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">mg/mL lidocaine HCl (anhyd.)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">mg/mL sodium chloride</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
</tbody>
</table>
<p>Multiple-dose vials contain 0.1% of methylparaben added as preservative. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH is 6.5 (5.0 to 7.0). See <span class="Bold Italics"><span class="Emphasis">HOW SUPPLIED</span></span> section for various sizes and strengths.</p>
<p>Lidocaine is a local anesthetic of the amide type.</p>
<p>Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate, a white powder freely soluble in water. The molecular weight is 288.82. It has the following structural formula:</p>
<p><img alt="structural formula lidocaine hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-02.jpg"></p>
<p>The semi-rigid vial used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b32403d3-354b-46cb-ae48-4b5c1b88fa53"></a><a name="section-15"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Mechanism of action:</span></span> Lidocaine stabilizes the        neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction        of impulses, thereby effecting local anesthetic action.</p>
<p><span class="Bold"><span class="Emphasis">Hemodynamics:</span></span> Excessive blood levels may cause        changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance, and mean arterial pressure. With        central neural blockade these changes may be attributable to block of autonomic fibers, a        direct depressant effect of the local anesthetic agent on various components of the        cardiovascular system and/or the beta-adrenergic receptor stimulating action of epinephrine        when present. The net effect is normally a modest <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> when the recommended dosages        are not exceeded.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics and metabolism:</span></span> Information        derived from diverse formulations, concentrations and usages reveals that lidocaine is        completely absorbed following parenteral administration, its rate of absorption depending,        for example, upon various factors such as the site of administration and the presence or        absence of a vasoconstrictor agent. Except for intravascular administration, the highest        blood levels are obtained following intercostal nerve block and the lowest after subcutaneous        administration.</p>
<p>The plasma binding of lidocaine is dependent on drug concentration, and the        fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of        free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent        on the plasma concentration of the alpha-1-acid glycoprotein.</p>
<p>Lidocaine crosses the blood-brain and placental barriers, presumably by passive        diffusion.</p>
<p>Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug        are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring        hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major        pathway of biotransformation, yields the metabolites monoethylglycinexylidide and        glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar        to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is        excreted in the form of various metabolites, and less than 10% is excreted unchanged. The        primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.</p>
<p>The elimination half-life of lidocaine following an intravenous bolus injection is        typically 1.5 to 2.0 hours. Because of the rapid rate at which lidocaine is metabolized, any        condition that affects liver function may alter lidocaine kinetics. The half-life may be        prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not        affect lidocaine kinetics but may increase the accumulation of metabolites.</p>
<p>Factors such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and the use of CNS stimulants and depressants affect the        CNS levels of lidocaine required to produce overt systemic effects. Objective adverse        manifestations become increasingly apparent with increasing venous plasma levels above 6.0        mcg free base per mL. In the rhesus monkey arterial blood levels of 18-21 mcg/mL have been        shown to be threshold for convulsive activity.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a3d734fd-fe42-4985-a278-b6c385b13cb6"></a><a name="section-16"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is indicated for production of local or        regional anesthesia by infiltration techniques such as percutaneous injection and intravenous        regional anesthesia by peripheral nerve block techniques such as brachial plexus and        intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when        the accepted procedures for these techniques as described in standard textbooks are       observed.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="d8759c45-f178-4a64-af1d-38662779adbf"></a><a name="section-17"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lidocaine is contraindicated in patients with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>        to local anesthetics of the amide type.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b5ad8057-f48b-482f-b8f2-ac7b994ea894"></a><a name="section-18"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LIDOCAINE HYDROCHLORIDE INJECTION, FOR INFILTRATION AND NERVE BLOCK, SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE <span class="Bold"><span class="Emphasis">IMMEDIATE</span></span> AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT, AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (See also <span class="Bold Italics"><span class="Emphasis">ADVERSE REACTIONS</span></span> and <span class="Bold Italics"><span class="Emphasis">PRECAUTIONS</span></span>). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">ACIDOSIS</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span> AND, POSSIBLY, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
<p>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving such infusions. The majority of reported cases of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have involved the shoulder joint; cases of gleno-humeral <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span>; patients who experienced <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.</p>
<p>To avoid intravascular injection, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be performed before the local anesthetic solution is injected. The needle must be repositioned until no return of blood can be elicited by <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p>Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="aedfc012-2bf3-43b5-a741-a790b2f48fdd"></a><a name="section-19"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="b9ac3889-dad8-4530-837d-acb5432729c6"></a><a name="section-19.1"></a><p></p>
<h2>General:</h2>
<p class="First">The safety and effectiveness of lidocaine depend on proper dosage, correct          technique, adequate precautions, and readiness for emergencies. Standard textbooks should          be consulted for specific techniques and precautions for various regional anesthetic          procedures.</p>
<p>Resuscitative equipment, oxygen, and other resuscitative drugs should be          available for immediate use. (See <span class="Bold Italics"><span class="Emphasis">WARNINGS</span></span> and <span class="Bold Italics"><span class="Emphasis">ADVERSE REACTIONS</span></span>). The lowest dosage that results in effective anesthesia should be used to avoid          high plasma levels and serious adverse effects. Syringe <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> should also be          performed before and during each supplemental injection when using indwelling catheter          techniques. During the administration of epidural anesthesia, it is recommended that a test          dose be administered initially and that the patient be monitored for central nervous system          toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal          administration before proceeding. When clinical conditions permit, consideration should be          given to employing local anesthetic solutions that contain epinephrine for the test dose          because circulatory changes compatible with epinephrine may also serve as a warning sign of          unintended intravascular injection. An intravascular injection is still possible even if          <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> for blood are negative. Repeated doses of lidocaine may cause significant          increases in blood levels with each repeated dose because of slow accumulation of the drug          or its metabolites. Tolerance to elevated blood levels varies with the status of the          patient. Debilitated, elderly patients, acutely ill patients and children should be given          reduced doses commensurate with their age and physical condition. Lidocaine should also be          used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Lumbar and caudal epidural          anesthesia should be used with extreme caution in persons with the following conditions:          existing neurological disease, spinal deformities, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> and severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Local anesthetic solutions containing a vasoconstrictor should be used cautiously          and in carefully circumscribed quantities in areas of the body supplied by end arteries or          having otherwise compromised blood supply. Patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> and          those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.          Ischemic injury or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> may result. Preparations containing a vasoconstrictor should be          used with caution in patients during or following the administration of potent general          anesthetic agents, since <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur under such conditions.</p>
<p>Careful and constant monitoring of cardiovascular and respiratory (adequacy of          ventilation) vital signs and the patientâ€™s state of consciousness should be          accomplished after each local anesthetic injection. It should be kept in mind at such times          that <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or          <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Since amide-type local anesthetics are metabolized by the liver, lidocaine should          be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients with severe hepatic          disease, because of their inability to metabolize local anesthetics normally, are at          greater risk of developing toxic plasma concentrations. Lidocaine should also be used with          caution in patients with impaired cardiovascular function since they may be less able to          compensate for functional changes associated with the prolongation of A-V conduction          produced by these drugs. Many drugs used during the conduct of anesthesia are considered          potential triggering agents for familial <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. Since it is not known          whether amide-type local anesthetics may trigger this reaction and since the need for          supplemental general anesthesia cannot be predicted in advance, it is suggested that a          standard protocol for the management of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> should be available. Early          unexplained signs of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>          may precede temperature elevation. Successful outcome is dependent on early diagnosis,          prompt discontinuance of the suspect triggering agent(s) and institution of treatment,          including oxygen therapy, indicated supportive measures and dantrolene (consult dantrolene          sodium intravenous package insert before using).</p>
<p>Proper tourniquet technique, as described in publications and standard textbooks,          is essential in the performance of intravenous regional anesthesia. Solutions containing          epinephrine or other vasoconstrictors should not be used for this technique.</p>
<p>Lidocaine should be used with caution in persons with known drug sensitivities.          Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine,          etc.) have not shown cross sensitivity to lidocaine.</p>
<p><span class="Bold"><span class="Emphasis">Use in the Head and Neck Area:</span></span> Small doses of          local anesthetics injected into the head and neck area, including retrobulbar, dental and          stellate <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blocks, may produce adverse reactions similar to systemic toxicity seen          with unintentional intravascular injections of larger doses. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,          <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> and cardiovascular stimulation or          <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have been reported. These reactions may be due to intra-arterial injections of          the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving          these blocks should have their circulation and respiration monitored and be constantly          observed. Resuscitative equipment and personnel for treating adverse reactions should be          immediately available. Dosage recommendations should not be exceeded. (See <span class="Bold Italics"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="d02dbd9c-b14a-41e7-97a7-75a02813ea68"></a><a name="section-19.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">When appropriate, patients should be informed in advance that they may experience          temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and motor activity, usually in the lower half of the body          following proper administration of epidural anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ed06d08b-cbf7-47f7-a3a9-9def2e7b70f7"></a><a name="section-19.3"></a><p></p>
<h2>Clinically Significant Drug Interactions:</h2>
<p class="First">The administration of local anesthetic solutions containing epinephrine or          norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic          antidepressants may produce severe prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of          epinephrine.</p>
<p>Concurrent use of these agents should generally be avoided. In situations when          concurrent therapy is necessary, careful patient monitoring is essential.</p>
<p>Concurrent administration of vasopressor drugs (for the treatment of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>          related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent          <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="cb911dd0-55aa-4d36-b19d-40c2a26d03ae"></a><a name="section-19.4"></a><p></p>
<h2>Drug Laboratory Test Interactions:</h2>
<p class="First">The intramuscular injection of lidocaine may result in an increase in creatine          phosphokinase levels. Thus, the use of this enzyme determination without isoenzyme          separation as a diagnostic test for the presence of <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> may be          compromised by the intramuscular injection of lidocaine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="d0465307-215b-42f9-bbd4-597bcb5a7015"></a><a name="section-19.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic          potential or the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="e6593aba-31ea-4e41-9be9-dcb82a6f96c5"></a><a name="section-19.6"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Teratogenic Effects. Pregnancy Category B.</span></span>          Reproduction studies have been performed in rats at doses up to 6.6 times the human dose          and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however,          no adequate and well-controlled studies in pregnant women. Animal reproduction studies are          not always predictive of human response. General consideration should be given to this fact          before administering lidocaine to women of childbearing potential, especially during early          pregnancy when maximum organogenesis takes place.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ad368f77-241c-40e8-a2d9-f77bb055cefa"></a><a name="section-19.7"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">Local anesthetics rapidly cross the placenta and when used for epidural,          paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal,          fetal and neonatal toxicity (See <span class="Bold Italics"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>â€”<span class="Bold"><span class="Emphasis">Pharmacokinetics</span></span>). The potential          for toxicity depends upon the procedure performed, the type and amount of drug used, and          the technique of drug administration. Adverse reactions in the parturient, fetus and          neonate involve alterations of the central nervous system peripheral vascular tone and          cardiac function.</p>
<p>Maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has resulted from regional anesthesia. Local anesthetics          produce vasodilation by blocking sympathetic nerves. Elevating the patientâ€™s          legs and positioning her on her left side will help prevent decreases in blood pressure.          The fetal heart rate also should be monitored continuously, and electronic fetal monitoring          is highly advisable.</p>
<p>Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of          parturition through changes in uterine contractility or maternal expulsive efforts. In one          study, paracervical block anesthesia was associated with a decrease in the mean duration of          first stage labor and facilitation of cervical dilation. However, spinal and epidural          anesthesia have also been reported to prolong the second stage of labor by removing the          parturientâ€™s reflex urge to bear down or by interfering with motor function. The          use of obstetrical anesthesia may increase the need for forceps assistance.</p>
<p>The use of some local anesthetic drug products during labor and delivery may be          followed by diminished muscle strength and tone for the first day or two of life. The          long-term significance of these observations is unknown. <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">Fetal bradycardia</span> may occur in 20          to 30 percent of patients receiving paracervical nerve block anesthesia with the amide-type          local anesthetics and may be associated with <span class="product-label-link" type="condition" conceptid="4344632" conceptname="Fetal acidosis">fetal acidosis</span>. Fetal heart rate should always          be monitored during paracervical anesthesia. The physician should weigh the possible          advantages against risks when considering paracervical block in <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, toxemia of          pregnancy and <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>. Careful adherence to recommended dosage is of the utmost          importance in obstetrical paracervical block. Failure to achieve adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with          recommended doses should arouse suspicion of intravascular or fetal intracranial injection.          Cases compatible with unintended fetal intracranial injection of local anesthetic solution          have been reported following intended paracervical or pudendal block or both. Babies so          affected present with unexplained neonatal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> at birth, which correlates with high          local anesthetic serum levels, and often manifest <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> within six hours. Prompt use of          supportive measures combined with forced urinary excretion of the local anesthetic has been          used successfully to manage this complication.</p>
<p>Case reports of maternal <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> following use of          some local anesthetics for paracervical block in early pregnancy (as anesthesia for          elective abortion) suggest that systemic absorption under these circumstances may be rapid.          The recommended maximum dose of each drug should not be exceeded. Injection should be made          slowly and with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Allow a 5-minute interval between sides.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="a4698bba-cb8b-424e-aaa6-29a88dbc5b92"></a><a name="section-19.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs          are excreted in human milk, caution should be exercised when lidocaine is administered to a          nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="d39ff672-1b87-4753-95e4-181b82409016"></a><a name="section-19.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Dosages in pediatric patients should be reduced, commensurate with age, body          weight and physical condition. See <span class="Bold Italics"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span><span class="Bold Italics"><span class="Emphasis">.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b5d71aee-9fed-4b73-ac72-46e23cb6aa08"></a><a name="section-20"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Systemic:</span></span> Adverse experiences following the        administration of lidocaine are similar in nature to those observed with other amide local        anesthetic agents. These adverse experiences are, in general, dose-related and may result        from high plasma levels caused by excessive dosage, rapid absorption or inadvertent        intravascular injection, or may result from a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy or diminished        tolerance on the part of the patient. Serious adverse experiences are generally systemic in        nature. The following types are those most commonly reported:</p>
<p><span class="Bold"><span class="Emphasis">Central Nervous System:</span></span> CNS manifestations are        excitatory and/or depressant and may be characterized by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>,        <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, blurred or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>,        <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensations of heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,        <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and arrest. The excitatory manifestations may be very        brief or may not occur at all, in which case the first manifestation of toxicity may be        <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> following the administration of lidocaine is usually an early sign of a        high blood level of the drug and may occur as a consequence of rapid absorption.</p>
<p><span class="Bold"><span class="Emphasis">Cardiovascular System:</span></span> Cardiovascular        manifestations are usually depressant and are characterized by <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and        <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, which may lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p><span class="Bold"><span class="Emphasis">Allergic:</span></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> are characterized        by cutaneous lesions, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may        occur as a result of sensitivity either to local anesthetic agents or to the methylparaben        used as a preservative in multiple dose vials. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> as a result of sensitivity        to lidocaine are extremely rare and, if they occur, should be managed by conventional means.        The detection of sensitivity by skin testing is of doubtful value.</p>
<p><span class="Bold"><span class="Emphasis">Neurologic:</span></span> The incidences of adverse reactions        associated with the use of local anesthetics may be related to the total dose of local        anesthetic administered and are also dependent upon the particular drug used, the route of        administration and the physical status of the patient. In a prospective review of 10,440        patients who received lidocaine for spinal anesthesia, the incidences of adverse reactions        were reported to be about 3 percent each for positional <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>;        2 percent for <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>; and less than 1 percent each for peripheral nerve symptoms, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,        respiratory inadequacy and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>. Many of these observations may be related to local        anesthetic techniques, with or without a contribution from the local anesthetic.</p>
<p>In the practice of caudal or lumbar epidural block, occasional unintentional        penetration of the subarachnoid space by the catheter may occur. Subsequent adverse effects        may depend partially on the amount of drug administered subdurally.</p>
<p>These may include spinal block of varying magnitude (including total spinal block),        <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> secondary to spinal block, loss of bladder and bowel control, and loss of        perineal sensation and sexual function. Persistent motor, sensory and/or autonomic (sphincter        control) deficit of some lower spinal segments with slow recovery (several months) or        incomplete recovery have been reported in rare instances when caudal or lumbar epidural block        has been attempted. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have also been noted following use of these        anesthetic procedures.</p>
<p>There have been reported cases of permanent injury to extraocular muscles requiring        surgical repair following retrobulbar administration.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="d514f782-068f-4d96-a0ca-7d54f8bbd0b3"></a><a name="section-21"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see<span class="Bold Italics"><span class="Emphasis"> ADVERSE REACTIONS, </span></span><span class="Bold Italics"><span class="Emphasis">WARNINGS</span></span> and <span class="Bold Italics"><span class="Emphasis">PRECAUTIONS</span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Management of Local Anesthetic Emergencies:</span></span> The first consideration is prevention, best accomplished by careful monitoring of cardiovascular and respiratory vital signs and the patientâ€™s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.</p>
<p>The first step in the management of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, as well as underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> sometimes depress the circulation when administered intravenously. Should <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).</p>
<p>If not treated immediately, both <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can result in <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if ventilatory support is not instituted. If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur standard cardiopulmonary resuscitative measures should be instituted.</p>
<p>Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated.</p>
<p>Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.</p>
<p>The oral LD<span class="Sub">50</span> of lidocaine HCl in non-fasted female rats is 459 (346âˆ’773) mg/kg (as the salt) and 214 (159âˆ’324) mg/kg (as the salt) in fasted female rats.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f2b072b9-3c6f-49e9-b937-29d8f6f311ed"></a><a name="section-22"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Lidocaine Hydrochloride Injection, USP for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required only solutions containing epinephrine should be used, except in those cases where vasopressor drugs may be contraindicated.</p>
<p>There have been adverse event reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.Â  Lidocaine is not approved for this use (see <span class="Bold Italics"><span class="Emphasis">WARNINGS</span></span> and <span class="Bold Italics"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>).</p>
<p>These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for elderly and debilitated patients and patients with cardiac and/or liver disease.</p>
<p>The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of Lidocaine Hydrochloride Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of Lidocaine Hydrochloride Injection may result in a more profound <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> when used in epidural anesthesia. Although the incidence of side effects with lidocaine is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.</p>
<p>For intravenous regional anesthesia, only the 50 mL single-dose vial containing 0.5% Lidocaine Hydrochloride Injection, USP should be used.</p>
<p><span class="Bold"><span class="Emphasis">Epidural Anesthesia</span></span></p>
<p>For epidural anesthesia, only the following <span class="Underline"><span class="Emphasis">available</span></span> specific products of Lidocaine Hydrochloride Injection by Hospira are recommended:</p>
<p>1%. . . . . . . . . . . . . . . . . . . . 30 mL single-dose teartop vials</p>
<p>1.5%. . . . . . . . . . . . . . . . . . . . . . . 20 mL single-dose ampuls</p>
<p>2%. . . . . . . . . . . . . . . . . . . . . . . . . 10 mL single-dose ampuls</p>
<p>Although these solutions are intended specifically for epidural anesthesia, they may also be used for infiltration and peripheral nerve block provided they are employed as single dose units. These solutions contain no bacteriostatic agent. In epidural anesthesia, the dosage varies with the number of dermatomes to be anesthetized (generally 2âˆ’3 mL of the indicated concentration per dermatome).</p>
<p><span class="Bold"><span class="Emphasis">Caudal and Lumbar Epidural Block:</span></span> As a precaution against the adverse experiences sometimes observed following unintentional penetration of the subarachnoid space, a test dose such as 2âˆ’3 mL of 1.5% lidocaine hydrochloride should be administered at least 5 minutes prior to injecting the total volume required for a lumbar or caudal epidural block. The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose (10âˆ’15 mcg have been suggested), may serve as a warning of unintentional intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient "epinephrine response" within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure. Adequate time should be allowed for onset of anesthesia after administration of each test dose. The rapid injection of a large volume of Lidocaine Hydrochloride Injection through the catheter should be avoided, and, when feasible, fractional doses should be administered.</p>
<p>In the event of the known injection of a large volume of local anesthetic solutions into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.</p>
<p><span class="Bold"><span class="Emphasis">Maximum Recommended Dosages</span></span></p>
<p><span class="Bold"><span class="Emphasis">NOTE: The products accompanying this insert do not contain epinephrine.</span></span></p>
<p><span class="Bold"><span class="Emphasis">Adults:</span></span> For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight and in general it is recommended that the maximum total dose not exceed 500 mg. When used without epinephrine, the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight and in general it is recommended that the maximum total dose does not exceed 300 mg. For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes. When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.</p>
<p>The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total. One-half of the total dose is usually administered to each side. Inject slowly five minutes between sides. (See also discussion of paracervical block in <span class="Bold Italics"><span class="Emphasis">PRECAUTIONS</span></span>).</p>
<p>For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.</p>
<p><span class="Bold"><span class="Emphasis">Children:</span></span> It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and normal body development, the maximum dose is determined by the childâ€™s age and weight. For example, in a child of 5 years weighing 50 lbs., the dose of lidocaine HCl should not exceed 75 â€” 100 mg (1.5 â€” 2 mg/lb). The use of even more dilute solutions (i.e., 0.25 â€” 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children.</p>
<p>In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times. In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions that are discolored and/or contain particulate matter should not be used. </p>
<table>
<colgroup><col align="left"></colgroup>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Table 1</span></span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Recommended Dosages of Lidocaine Hydrochloride Injection, USP for Various Anesthetic</span></span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Procedures in Normal Healthy Adults</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Lidocaine Hydrochloride Injection, USP (without Epinephrine)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Procedure</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Conc. (%)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Vol. (mL)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Total Dose (mg)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold Italics"><span class="Emphasis">Infiltration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Percutaneous</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5 or 1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1âˆ’60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Intravenous Regional</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10âˆ’60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold Italics"><span class="Emphasis">Peripheral Nerve Blocks, e.g.</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Brachial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15âˆ’20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Dental</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1âˆ’5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20âˆ’100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Intercostal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Paravertebral</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3âˆ’5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30âˆ’50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Pudendal (each side)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Paracervical</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">(each side)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold Italics"><span class="Emphasis">Sympathetic Nerve Blocks, e.g.</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Cervical (stellate <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Lumbar</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5âˆ’10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50âˆ’100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold Italics"><span class="Emphasis">Central Neural Blocks</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Epidural*</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Thoracic</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20âˆ’30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Lumbar</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25âˆ’30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Anesthesia</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15âˆ’20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10âˆ’15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Caudal</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20âˆ’30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Surgical Anesthesia</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15âˆ’20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225âˆ’300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First">*Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome).</p></td></tr>
</tbody>
</table>
<p>THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE. OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.</p>
<p><span class="Bold"><span class="Emphasis">Sterilization, Storage and Technical Procedures:</span></span> Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection as they have been related to incidence of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. When chemical disinfection of multi-dose vials is desired, either isopropyl alcohol (91%) or 70% ethyl alcohol is recommended. Many commercially available brands of rubbing alcohol, as well as solutions of ethyl alcohol not of USP grade, contain denaturants which are injurious to rubber and, therefore, are not to be used. It is recommended that chemical disinfection be accomplished by wiping the vial stopper thoroughly with cotton or gauze that has been moistened with the recommended alcohol just prior to use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="b800de14-94bc-451a-aeff-7d3a3e536588"></a><a name="section-23"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is supplied as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Container</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Size</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Total (mg)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Single-dose:</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4278-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL (bulk â€“ 400 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL (bulk â€“ 400 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-62</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL (bulk â€“ 800 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-65</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL (bulk â€“ 800 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4279-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4270-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Sterile Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4776-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5% (15 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4056-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Sterile Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5% (15 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4282-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4282-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Multiple-dose:</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4275-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4276-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4276-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">500</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4277-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">400</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4277-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1000</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Single-dose products are preservative-free.</p>
<p>Store at 20 to 25Â°C (68 to 77Â°F). [See USP Controlled Room Temperature.]</p>
<p>Lidocaine Hydrochloride Injection, USP solutions packaged in ampuls and glass teartop vials may be autoclaved one time only. Autoclave at 15 pounds pressure, 121Â°C (250Â°F) for 15 minutes. <span class="Bold"><span class="Emphasis">DO NOT AUTOCLAVE PRODUCT IN PLASTIC VIALS. </span></span></p>
<p>Revised: February, 2010</p>
<p>Printed in USAÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EN-2421</p>
<p>Hospira, Inc., Lake Forest, IL 60045 USA</p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="LINK_109c5863-a442-41f6-9f71-8e8c0f387630"></a><a name="section-24"></a><p></p>
<h1>Active ingredient(s)</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span> (15%)</p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="LINK_01479b51-b667-49f0-920e-90c39be5ce78"></a><a name="section-25"></a><p></p>
<h1>Purpose</h1>
<p class="First">Â Inhalant</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_1eeeb6da-e553-4c69-a043-9f5801eadc71"></a><a name="section-26"></a><p></p>
<h1>Use(s)</h1>
<p class="First">To prevent or treat <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_c6f72f3e-88b8-49ad-a9fd-33c44763f6b6"></a><a name="section-27"></a><p></p>
<h1>Warnings</h1>
<p class="First">Keep away from the Eyes.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9f7f945e-f8df-45cf-8034-37ef2d0f0cb4"></a><a name="section-27.1"></a><p></p>
<h2>For external use only</h2>
</div>
<div class="Section" data-sectionCode="50566-9">
<a name="LINK_9c820a4e-c9a6-417c-b63c-2e03abb88a0a"></a><a name="section-27.2"></a><p></p>
<h2>Stop use and ask a doctor if</h2>
<p class="First">Â condition persists</p>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="LINK_e19d9722-653b-4975-ba5a-518bfb687e97"></a><a name="section-27.3"></a><p></p>
<h2>Keep out of reach of children</h2>
<p class="First">Â If swallowed, get medical help or contact a Poison Control Center right away.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e4d6ab1b-73de-4900-9d1c-8466d3115da9"></a><a name="section-28"></a><p></p>
<h1>Directions</h1>
<p class="First">Â Directions: hold inhalant away from face and crush between thumb and forefinger. Carefully approach crushed inhalant to nostrils of affected person.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e6e53025-68a8-4243-8d11-c07a2ac5dfe5"></a><a name="section-29"></a><p></p>
<h1>Other information</h1>
<p class="First">Â Store at room temperature away from light.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_fd4fe80b-9fd4-4d5c-aa59-24589eb364f7"></a><a name="section-30"></a><p></p>
<h1>Storage</h1>
<p class="First">Â Store at 20ÂºC to 25ÂºC (68ÂºF to 77ÂºF)</p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="LINK_7a0b3be0-6853-4f9c-b9d4-41d68e0ceebc"></a><a name="section-31"></a><p></p>
<h1>Inactive ingredients</h1>
<p class="First">Â Alcohol USP, FDC red dye 40, lavender oil fcc, lemon oil fcc, nutmeg oil fcc, purified water usp</p>
</div>
<div class="Section" data-sectionCode="53413-1">
<a name="LINK_460542a9-85fe-4b7c-b34f-aa12ba49cee7"></a><a name="section-32"></a><p></p>
<h1>Questions</h1>
<p class="First">Â Questions? Call 1-866-390-4411 Mon - Fri 9:00 AM - 5:00 PM</p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="d2"></a><a name="section-33"></a><p></p>
<h1>Active ingredient</h1>
<p class="First">Povidone-Iodine USP 10% w/w (equivalent to 1.0% titratable iodine)</p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="d3"></a><a name="section-34"></a><p></p>
<h1>Purpose</h1>
<p class="First">Antiseptic</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d4"></a><a name="section-35"></a><p></p>
<h1>Uses</h1>
<ul>
<li>Healthcare antiseptic for preparation of the skin prior to surgery</li>
<li>First Aid antiseptic to help prevent the risk of <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span> in minor cut, scrapes and <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="d5"></a><a name="section-36"></a><p></p>
<h1>Warnings</h1>
<p class="First">For external use only<br><br>Do not use<br><br></p>
<ul>
<li>in the eyes</li>
<li>on individuals who are allergic or sensitive to iodine</li>
<li>over large areas of the body</li>
<li>as a first aid antiseptic longer than one week unless directed by a doctor</li>
</ul>
<p>Discontinue use if irritation and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> develop. If condition persist for more than 72 hours consult a doctor.<br><br>Consult a doctor in case of<br></p>
<ul>
<li>Deep or puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span></li>
<li>animal bites</li>
<li>serious <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</li>
</ul>
<div class="Section" data-sectionCode="50566-9">
<a name="i4i_OTC_Stop_Use_id_e895f834-8f2e-43b0-b9c8-91a5f60ac7ba"></a><a name="section-36.1"></a><p></p>
<h2>Stop use and ask a doctor if</h2>
<p class="First">the condition persists or gets worse.</p>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="i4i_OTC_Keep_Away_Children_id_0da6f677-3908-4431-84b1-dbd0678bc6ca"></a><a name="section-36.2"></a><p></p>
<h2>Keep out of reach of children.</h2>
<p class="First">If swallowed, get medical help or contact a Poison Control Center right away.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d6"></a><a name="section-37"></a><p></p>
<h1>Directions</h1>
<p class="First">For the preparation of the skin prior to surgery<br></p>
<ul>
<li>clean the treatment area</li>
<li>Remove swab by stick</li>
<li>apply to the operative site prior to surgery</li>
</ul>
<p>For use as a first aid antiseptic<br></p>
<ul>
<li>clean the treatment area</li>
<li>apply a small amount of this product on the treatment area 1-3 times daily</li>
<li>may be covered with a sterile bandage</li>
<li>if bandaged, let dry first</li>
</ul>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="d7"></a><a name="section-38"></a><p></p>
<h1>Other information</h1>
<ul>
<li>Store at room temperature</li>
<li>Avoid excessive heat</li>
</ul>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="d8"></a><a name="section-39"></a><p></p>
<h1>Inactive ingredients</h1>
<p class="First">Purified Water, Sodium Hydroxide</p>
</div>
<div class="Section" data-sectionCode="53413-1">
<a name="d9"></a><a name="section-40"></a><p></p>
<h1>Questions?</h1>
<p class="First">Professional Disposables International, Inc.<br>Orangeburg, NY 10962-1376<br>USA - 1-800-999-6423<br>www.pdipdi.comÂ Â Â Â Â Â Â Â  Made in USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d10"></a><a name="section-41"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - APMULE LABEL</span></p>
<p>CRUSH ONCE, USE AND DISCAR
</p>
<p>CRUSH --&gt; â—? &lt;-- HERE
</p>
<p>0.3 ml <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span> INHALANT
</p>
<p>A RESPIRATORY STIMULANT
</p>
<p>FOR INHALATION ONLY
</p>
<div class="Figure">
<a name="f03"></a><img alt="PRINCIPAL DISPLAY PANEL - APMULE LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d11"></a><a name="section-42"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - VIAL LABEL</span></p>
<p><span class="Bold">NDC 0003-0293-20  Rx only</span></p>
<p><span class="Bold">KENALOG-40Â®</span></p>
<p><span class="Bold">(Triamcinolone Acetonide Injectable Suspension, USP)</span></p>
<p>40 mg per 1 mL
</p>
<p>5 mL Multiple Dose Vial
</p>
<div class="Figure">
<a name="f04"></a><img alt="PRINCIPAL DISPLAY PANEL - VIAL LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d12"></a><a name="section-43"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - PREP PAD LABEL</span></p>
<p><span class="Bold">PDIÂ®</span></p>
<p>REORDER NO. C124
</p>
<p>NDC 10819-3883-3
</p>
<p><span class="Bold">Povidone-Iodine</span><span class="Bold">â€¨</span><span class="Bold">Prep Pad</span></p>
<p>Antiseptic/Germicide <span class="Bold">LARGE</span></p>
<p><span class="Bold">For Professional and Hospital Use</span></p>
<p>Professional Disposables International, Inc.
</p>
<p>Orangeburg, NY 10962-1376 Â· USA Â· 1-800-999-6423
</p>
<p>www.pdipdi.com Made in USA
</p>
<p><span class="Bold">1 Prep Pad</span> [1.7 x 3.5 in (4.4 x 8.8 cm)]
</p>
<div class="Figure">
<a name="f05"></a><img alt="PRINCIPAL DISPLAY PANEL - PREP PAD LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d13"></a><a name="section-44"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - SYRINGE LABEL</span></p>
<p><span class="Bold">2mL  NDC 0409-4713-32</span></p>
<p><span class="Bold">Preservative-Free  Rx only</span></p>
<p><span class="Bold">1% LIDOCAINE HCl</span></p>
<p>Injection, USP
</p>
<p><span class="Bold">10 mg/mL</span></p>
<p>RL-1045 (11/04)
</p>
<p>HOSPIRA, INC., LK. FOREST, IL 60045 USA
</p>
<div class="Figure">
<a name="f06"></a><img alt="PRINCIPAL DISPLAY PANEL - SYRINGE LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d14"></a><a name="section-45"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ KIT LABEL</span></p>
<p><span class="Bold">NDC 76420-0524-01  Rx-Only</span></p>
<p><span class="Bold">Physicians EZ Use</span></p>
<p><span class="Bold">Joint, Tunnel,</span></p>
<p><span class="Bold">and Trigger Kit</span></p>
<p><span class="Bold">Kit Contains:</span></p>
<p>1 Kenalog-40<span class="Bold"><span class="Sup">Â®</span></span> (1mL)*
</p>
<p>1 (2mL) Lidocaine HCl Injection, USP 1% (10mg/mL)*
</p>
<p>1 <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span> Inhalant Ampule (35% alcohol/15% <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span>)
</p>
<p>1 Povidone-Iodine Prep Pad
</p>
<p>1 Pair Sterile Latex Gloves - Size 7*
</p>
<p>1 CSR Wrap
</p>
<p><span class="Bold">1 Dose</span></p>
<p><span class="Bold">Enovachem</span><span class="Bold">â€¨</span>MANUFACTUING
</p>
<div class="Figure">
<a name="f07"></a><img alt="PRINCIPAL DISPLAY PANEL â€“KIT LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e25cfc22-29ba-473f-88c4-3c88e9f6863b&amp;name=phy0a-0000-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHYSICIAN EZ USE JOINT TUNNEL AND TRIGGER KITÂ 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, lidocaine hydrochloride, triamcinolone acetonide, povidone-iodine kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76420-524</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76420-524-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 AMPULE </td>
<td class="formItem">2Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">1 AMPULE </td>
<td class="formItem">0.3Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem">1 PACKET </td>
<td class="formItem">2.2Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>LIDOCAINE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">lidocaine hydrochloride anhydrous injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-4713</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INFILTRATION</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LIDOCAINE HYDROCHLORIDE</strong> (LIDOCAINE) </td>
<td class="formItem">LIDOCAINE HYDROCHLORIDE ANHYDROUS</td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-4713-32</td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080408</td>
<td class="formItem">03/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>KENALOG-40Â 		
					</strong><br><span class="contentTableReg">triamcinolone acetonide injection, suspension</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-0293</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRA-ARTICULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMCINOLONE ACETONIDE</strong> (TRIAMCINOLONE ACETONIDE) </td>
<td class="formItem">TRIAMCINOLONE ACETONIDE</td>
<td class="formItem">40Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>NITROGEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-0293-05</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA014901</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span> INHALANTSÂ 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> inhalants inhalant</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:39822-9900</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong> (<span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span>) </td>
<td class="formItem"><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></td>
<td class="formItem">0.045Â g Â inÂ 0.3Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LAVENDER OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>NUTMEG OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LEMON</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-9900-2</td>
<td class="formItem">0.3 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">02/14/1976</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>PVP IODINE PREP PADÂ 		
					MEDIUM AND LARGE</strong><br><span class="contentTableReg">providone iodine swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10819-3883</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POVIDONE-IODINE</strong> (IODINE) </td>
<td class="formItem">IODINE</td>
<td class="formItem">10Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10819-3883-3</td>
<td class="formItem">2.2 g in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">OTC monograph not final</td>
<td class="formItem">part333A</td>
<td class="formItem">01/01/1978</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA014901</td>
<td class="formItem">05/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>MedChem Manufacturing Inc. dba Enovachem
							(059888437)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Enovachem Manufacturing</td>
<td class="formItem"></td>
<td class="formItem">059888437</td>
<td class="formItem">REPACK(76420-524)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Professional Disposables International, Inc.</td>
<td class="formItem"></td>
<td class="formItem">800777117</td>
<td class="formItem">MANUFACTURE(10819-3883)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ee2ce525-4aa4-4bf6-9791-28beafdfa8ca</div>
<div>Set id: e25cfc22-29ba-473f-88c4-3c88e9f6863b</div>
<div>Version: 1</div>
<div>Effective Time: 20130530</div>
</div>
</div>Â <div class="DistributorName">MedChem Manufacturing Inc. dba Enovachem</div></p>
</body></html>
